Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 14/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.81 |
| ▸ | HTT | P42858 | 6/20 | 0.81 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.81 |
| ▸ | LMNA | P02545 | 4/20 | 0.81 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.81 |
| ▸ | NPY1R | P25929 | 1/20 | 0.81 |
| ▸ | NPY2R | P49146 | 1/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.74 |
| ▸ | MEN1 | O00255 | 5/20 | 0.74 |
| ▸ | HPGD | P15428 | 1/20 | 0.71 |
| ▸ | CRHBP | P24387 | 1/20 | 0.71 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.71 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | RAPGEF3 | O95398 | 5/20 | 0.54 |
| ▸ | RAPGEF4 | Q8WZA2 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL922713 | 1.00 | MAPT (0.81) | MAPTSMN1; SMN2HTTNPSR1LMNA | |
| SCHEMBL22340243 | 0.86 | RAPGEF3 (0.74) | MAPTSMN1; SMN2HTTNPSR1LMNA | |
| SCHEMBL22340245 | 0.85 | MAPT (0.81) | MAPTSMN1; SMN2HTTNPSR1LMNA | |
| SCHEMBL13505516 | 0.85 | MAPT (0.68) | MAPTSMN1; SMN2HTTNPSR1LMNA | |
| SCHEMBL9868178 | 0.84 | MAPT (0.65) | MAPTSMN1; SMN2HTTNPSR1LMNA | |
| SCHEMBL9868180 | 0.84 | MAPT (0.65) | MAPTSMN1; SMN2HTTNPSR1LMNA | |
| SCHEMBL16291929 | 0.79 | MAPT (0.58) | MAPTSMN1; SMN2HTTNPSR1LMNA | |
| SCHEMBL16291927 | 0.79 | MAPT (0.58) | MAPTSMN1; SMN2HTTNPSR1LMNA | |
| SCHEMBL9868268 | 0.79 | MAPT (0.58) | MAPTSMN1; SMN2HTTNPSR1LMNA | |
| SCHEMBL9868264 | 0.79 | MAPT (0.58) | MAPTSMN1; SMN2HTTNPSR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140107125-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | DERMIRA (CANADA), INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8445694-B2 | Hydrazonopyrazole derivatives and their use as therapeutics | DERMIRA (CANADA), INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20110237783-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | Valocor Therapeutics, Inc. (CA) | 2011-09-29 | — | — | US | disclosed |
| US-7875728-B2 | tert-butyl-[5-methyl-4-(phenylhydrazono)-4H-pyrazol-3-yl]amine; 4-(3-fluorophenylhydrazono)-5-methyl-2H-pyrazol-3-ylamine; demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death | Valocor Therapeutics, Inc. (CA) | 2011-01-25 | — | — | US | disclosed |
| US-20050272709-A1 | Immugenic compositions and diagnostic and therapeutic uses thereof | DERMIRA (CANADA), INC. | 2005-12-08 | — | — | US | disclosed |
| EP-1450791-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | Kinetek Pharmaceuticals, Inc. (CA) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003045379-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | KINETEK PHARMACEUTICALS, INC. (CA) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237783-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | CDK4, CCNI, BCL2 | MAPT 4573/4885SMN1; SMN2 4161/4885HTT 1145/4885 |
| US-20140107125-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | CDK4, CCNI, BCL2 | MAPT 4573/4885SMN1; SMN2 4161/4885HTT 1145/4885 |
| US-20050272709-A1 | Immugenic compositions and diagnostic and therapeutic uses thereof | MKI67, CDK4, CCNC | MAPT 4000/4885SMN1; SMN2 2243/4885HTT 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.